Smoking is one of the risk factors for the development of kidney cancer, and many other cancers. To help people make healthier choices and to save cash this New Year, the NHS is launching a Quit Smoking campaign, including an app with a free personal quit plan to help you.

See more on our website here:

Is there someone special in your life you would like to show your appreciation to?
Our glass hearts are a great way to do this, it could not be easier, email karen@actionkidneycancer.org with the number of hearts you would like, your chosen words from thank you, support, kindness and friendship and the addresses you want them posted to and add any personal message you would like.
The suggested minimum donation for each heart is £7.50 this includes the postage and packaging.
The money raised from this Christmas campaign will help us to continue supporting families affected by kidney cancer.
Thank you for your support. We are Stronger Together!
To donate please follow the link below:
https://www.justgiving.com/campaign/giftaheart
#giftaheart #kidneycancer #bypatientsforpatients

Further results are available from a trial comparing a diagnostic test called 89Zr-girentuximab PET/CT with conventional CT scans.

In the ZIRCON trial, there were major changes in clinical management for more than a third of patients due to 89Zr-girentuximab PET/CT imaging versus conventional imaging: such as a switch from biopsy to surgery, a switch from surgery to biopsy, partial nephrectomy to total nephrectomy, surgery to addition diagnostic tests and total nephrectomy to partial nephrectomy.

Nearly half of patients would have had a change in their clinical management plan based on 89Zr-girentuximab PET/CT imaging results.

This study confirms that 89Zr-DFO-girentuximab is well tolerated and can accurately identify kidney cancer from a PET/CT scan. This is promising for the management of kidney cancer patients.

Read more on our website here:

The long-term follow data from a study with belzutifan for the treatment of VHL-related tumours (including kidney cancer), reinforces the fact that belzutifan remains the only approved anti-cancer treatment for VHL-related cancers that do not need immediate surgery.

Read more on our website here:

Five-year follow-up data from the clinical trial comparing adjuvant pembrolizumab with placebo further support the use of adjuvant pembrolizumab as a standard treatment for patients with kidney cancer at high-risk of returning after surgery.

Read more on our website here: